Bioactive lipids and cancer metastasis to bone

Abstract

Bioactive lipids constitute a large family of molecules considered as inflammatory mediators. Among them, lysophosphatidic acid (LPA), sphingosine 1-phosphate (S1P), and eicosanoids (prostanoids such as PGE2 and leukotrienes such as LTB4, LTC4, and LTD4) play a central role in the pathophysiology of several inflammatory diseases. However, it has long been known that these bioactive lipids are also involved in cancer, mainly because of their ability to control the pro-inflammatory microenvironment of tumors as well as their ability to act directly on tumor cells promoting cell proliferation, migration, and survival. Recently, there has been increased interest in determining how these lipid mediators orchestrate tumor development and metastasis. Bone metastases result from a complex dialogue between tumor cells and bone cells. Recent findings demonstrate that all these bioactive lipids can profoundly affect bone metabolism by acting positively or negatively on both osteoblasts and osteoclasts. This review gives an overview of previous findings demonstrating direct involvement of LPA, S1P, and PGE2 in bone metastasis. This review also emphasizes the recent findings that characterize the activity of these bioactive lipids directly on bone cells and how these activities could be integrated into the complex molecular mechanisms leading to bone metastasis formation and progression.

Keywords

Lysophosphatidic acid / sphingosine 1-phosphate / eicosanoids / prostaglandins / leukotrienes / cancer / bone cells

References

[1] Paget S.The distribution of secondary growths in cancer of the breast.Lancet1989;133:571-3

[2] Mundy GR.Metastasis to bone: causes, consequences and therapeutic opportunities.Nat Rev Cancer2002;2:584-93

[3] Coleman RE,Padhani AR.Bone metastases.Nat Rev Dis Primers2020;6:83

[4] Aoki J,Okudaira S.Two pathways for lysophosphatidic acid production.Biochim Biophys Acta2008;1781:513-8

[5] Yung YC,Chun J.LPA receptor signaling: pharmacology, physiology, and pathophysiology.J Lipid Res2014;55:1192-214 PMCID:PMC4076099

[6] Bektas M,Liu H,Milstien S.A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells.J Cell Biol2005;169:801-11 PMCID:PMC2171605

[7] Tomsig JL,Berdyshev EV.Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo.Biochem J2009;419:611-8 PMCID:PMC2677185

[8] Saba JD.Lysophospholipids in development: Miles apart and edging in.J Cell Biochem2004;92:967-92

[9] Pagès C,Valet P.Lysophosphatidic acid synthesis and release.Prostaglandins Other Lipid Mediat2001;64:1-10

[10] van Meeteren LA,Stortelers C.Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.Mol Cell Biol2006;26:5015-22 PMCID:PMC1489177

[11] Stefan C,Bollen M.NPP-type ectophosphodiesterases: unity in diversity.Trends Biochem Sci2005;30:542-50

[12] Nikitopoulou I,Karouzakis E.Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis.J Exp Med2012;209:925-33 PMCID:PMC3348105

[13] Dusaulcy R,Grès S.Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid.J Lipid Res2011;52:1247-55 PMCID:PMC3090245

[14] Kanda H,Klein R,Gunn MD.Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs.Nat Immunol2008;9:415-23 PMCID:PMC2783613

[15] van Meeteren LA,Christodoulou E.Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.J Biol Chem2005;280:21155-61

[16] David M,Kikuta J.Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity.J Biol Chem2014;289:6551-64 PMCID:PMC3945319

[17] Alioli CA,Laurencin-Dalacieux S.Expression of the type 1 lysophosphatidic acid receptor in osteoblastic cell lineage controls both bone mineralization and osteocyte specification.Biochim Biophys Acta Mol Cell Biol Lipids2020;1865:158715

[18] Pasternack SM,Al Aboud K.G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth.Nat Genet2008;40:329-34

[19] Boucharaba A,Grès S.Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.J Clin Invest2004;114:1714-25 PMCID:PMC535068

[20] Blackburn J.The emerging role of lysophosphatidic acid (LPA) in skeletal biology.Bone2012;50:756-62

[21] Gennero I,Conte-Auriol F.Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass.Bone2011;49:395-403 PMCID:PMC3697734

[22] Liu YB,Bodine PV,Robinson JA.LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4.J Cell Biochem2010;109:794-800

[23] Lapierre DM,Pereverzev A.Lysophosphatidic acid signals through multiple receptors in osteoclasts to elevate cytosolic calcium concentration, evoke retraction, and promote cell survival.J Biol Chem2010;285:25792-801 PMCID:PMC2919141

[24] Karagiosis SA.Lysophosphatidic acid induces osteocyte dendrite outgrowth.Biochem Biophys Res Commun2007;357:194-9

[25] McMichael BK,Lee BS.c-Src-mediated phosphorylation of thyroid hormone receptor-interacting protein 6 (TRIP6) promotes osteoclast sealing zone formation.J Biol Chem2010;285:26641-51 PMCID:PMC2924104

[26] David M,Descotes F.Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.PLoS One2010;5:e9741 PMCID:PMC2840030

[27] Miyabe Y,Iwai Y.Necessity of lysophosphatidic acid receptor 1 for development of arthritis.Arthritis Rheum2013;65:2037-47

[28] Flammier S,Bourguillault F.Osteoclast-derived autotaxin, a distinguishing factor for inflammatory bone loss.Arthritis Rheumatol2019;71:1801-11 PMCID:PMC6817375

[29] Leblanc R,David M.Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone.Blood2014;124:3141-50 PMCID:PMC4231421

[30] Stracke ML,Unsworth EJ,Cioce V.Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein.J Biol Chem1992;267:2524-9

[31] Lin ME,Chun J.Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.Prostaglandins Other Lipid Mediat2010;91:130-8 PMCID:PMC2845529

[32] Choi JW,Noguchi K.LPA receptors: subtypes and biological actions.Annu Rev Pharmacol Toxicol2010;50:157-86

[33] Sedláková I,Tošner J.Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer.Tumour Biol2011;32:311-6

[34] Ikeda H,Ohkawa R,Yatomi Y.Plasma lysophosphatidic acid levels and hepatocellular carcinoma.Hepatology2013;57:417-8

[35] Xu Y,Casey G.Lysophospholipids activate ovarian and breast cancer cells.Biochem J1995;309:933-40 PMCID:PMC1135721

[36] Lin CI,Huang MT.Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA(1/3), COX-2, and NF-kappaB activation- and EGFR transactivation-dependent mechanisms.Cell Signal2008;20:1804-14

[37] Sitohy B,Dvorak HF.Anti-VEGF/VEGFR therapy for cancer: reassessing the target.Cancer Res2012;72:1909-14 PMCID:PMC3335750

[38] Bellahcène A,Detry C,Clézardin P.Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells.Breast Cancer Res Treat2007;101:135-48

[39] Wu X,Chen H.Lysophosphatidic acid induces interleukin-6 and CXCL15 secretion from MLO-Y4 cells through activation of the LPA₁ receptor and PKCθ signaling pathway.Int Immunopharmacol2019;74:105664

[40] Aki Y,Nakamura H.Lysophosphatidic acid-stimulated interleukin-6 and -8 synthesis through LPA1 receptors on human osteoblasts.Arch Oral Biol2008;53:207-13

[41] Peyruchaud O,Pécheur I,Delmas P.Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.J Bone Miner Res2001;16:2027-34

[42] Masuda A,Izutsu K.Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma.Br J Haematol2008;143:60-70

[43] Nakai Y,Nakamura K.Specific increase in serum autotaxin activity in patients with pancreatic cancer.Clin Biochem2011;44:576-81

[44] Zhang G,Xu S,Wang X.Expression of autotaxin mRNA in human hepatocellular carcinoma.Chin Med J (Engl)1999;112:330-2

[45] Benesch MG,Dewald J.Tumor-induced inflammation in mammary adipose tissue stimulates a vicious cycle of autotaxin expression and breast cancer progression.FASEB J2015;29:3990-4000

[46] Benesch MG,Tang X.Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer.Endocr Relat Cancer2015;22:593-607

[47] Guise TA,Taylor SD.Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.J Clin Invest1996;98:1544-9 PMCID:PMC507586

[48] Aielli F,Rucci N.Bone metastasis pain, from the bench to the bedside.Int J Mol Sci2019;20:280 PMCID:PMC6359191

[49] Yoneda T,Nakanishi M.Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain.Bone2011;48:100-5

[50] Zhao J,Li TT,Wei JY.The sensitization of peripheral C-fibers to lysophosphatidic acid in bone cancer pain.Life Sci2010;87:120-5

[51] Pan HL,Zhao ZQ.Involvement of lysophosphatidic acid in bone cancer pain by potentiation of TRPV1 via PKCε pathway in dorsal root ganglion neurons.Mol Pain2010;6:85 PMCID:PMC3004845

[52] Wu JX,Wang Q,Xu MY.Rho/ROCK acts downstream of lysophosphatidic acid receptor 1 in modulating P2X3 receptor-mediated bone cancer pain in rats.Mol Pain2016;12:174480691664492 PMCID:PMC4956381

[53] D'avanzo N.Lipid regulation of sodium channels.Curr Top Membr2016;78:353-407

[54] Hannun YA.Principles of bioactive lipid signalling: lessons from sphingolipids.Nat Rev Mol Cell Biol2008;9:139-50

[55] Kitatani K,Hannun YA.The sphingolipid salvage pathway in ceramide metabolism and signaling.Cell Signal2008;20:1010-8 PMCID:PMC2422835

[56] Hannun YA.Sphingolipids and their metabolism in physiology and disease.Nat Rev Mol Cell Biol2018;19:175-91 PMCID:PMC5902181

[57] Ramos-Perez WD,Escalante-Alcalde D,Schwab SR.A map of the distribution of sphingosine 1-phosphate in the spleen.Nat Immunol2015;16:1245-52 PMCID:PMC4690472

[58] Schwab SR,Matloubian M,Huang Y.Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients.Science2005;309:1735-9

[59] Yanagida K.Vascular and immunobiology of the circulatory sphingosine 1-phosphate gradient.Annu Rev Physiol2017;79:67-91 PMCID:PMC5500220

[60] Sartawi Z,Ryan KB.Sphingosine 1-phosphate (S1P) signalling: Role in bone biology and potential therapeutic target for bone repair.Pharmacol Res2017;125:232-45 PMCID:PMC7253298

[61] Vu TM,Foo JC.Mfsd2b is essential for the sphingosine-1-phosphate export in erythrocytes and platelets.Nature2017;550:524-8

[62] Proia RL.Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.J Clin Invest2015;125:1379-87 PMCID:PMC4409021

[63] Thuy AV,Hemdan NY.Sphingosine 1-phosphate in blood: function, metabolism, and fate.Cell Physiol Biochem2014;34:158-71

[64] Christoffersen C,Kumaraswamy SB.Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M.Proc Natl Acad Sci U S A2011;108:9613-8 PMCID:PMC3111292

[65] Obinata H,Wada Y.Identification of ApoA4 as a sphingosine 1-phosphate chaperone in ApoM- and albumin-deficient mice.J Lipid Res2019;60:1912-21 PMCID:PMC6824498

[66] Cyster JG.Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs.Annu Rev Immunol2012;30:69-94

[67] Hla T,Michaud J.The vascular S1P gradient-cellular sources and biological significance.Biochim Biophys Acta2008;1781:477-82 PMCID:PMC2636563

[68] Chun J,Lynch KR,Moolenaar WH.International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.Pharmacol Rev2010;62:579-87 PMCID:PMC2993255

[69] Rosen H,Hanson M,Oldstone MB.Sphingosine-1-phosphate and its receptors: structure, signaling, and influence.Annu Rev Biochem2013;82:637-62

[70] Ishii M.Sphingosine-1-phosphate signaling controlling osteoclasts and bone homeostasis.Biochim Biophys Acta2013;1831:223-7

[71] Keller J,Huebner AK.Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts.Nat Commun2014;5:5215 PMCID:PMC4205484

[72] Ryu J,Chang EJ,Banno Y.Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling.EMBO J2006;25:5840-51 PMCID:PMC1698879

[73] Ishii M,Shimazu Y,Germain RN.Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo.J Exp Med2010;207:2793-8 PMCID:PMC3005230

[74] Ishii T,Nishiyama I,Ishii M.The role of sphingosine 1-phosphate in migration of osteoclast precursors; an application of intravital two-photon microscopy.Mol Cells2011;31:399-403 PMCID:PMC3887611

[75] Weske S,Reese A.Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss.Nat Med2018;24:667-78

[76] Pederson L,Westendorf JJ,Oursler MJ.Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate.Proc Natl Acad Sci U S A2008;105:20764-9 PMCID:PMC2603259

[77] Lotinun S,Matsubara T.Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation.J Clin Invest2013;123:666-81 PMCID:PMC3561821

[78] Bae SJ,Ahn SH,Kim BJ.The circulating sphingosine-1-phosphate level predicts incident fracture in postmenopausal women: a 3.5-year follow-up observation study.Osteoporos Int2016;27:2533-41

[79] Weske S,von Wnuck Lipinski K.Agonist-induced activation of the S1P receptor 2 constitutes a novel osteoanabolic therapy for the treatment of osteoporosis in mice.Bone2019;125:1-7

[80] Ogretmen B.Sphingolipid metabolism in cancer signalling and therapy.Nat Rev Cancer2018;18:33-50 PMCID:PMC5818153

[81] Oshi M,Tokumaru Y.Intra-tumoral angiogenesis is associated with inflammation, immune reaction and metastatic recurrence in breast cancer.Int J Mol Sci2020;21:6708 PMCID:PMC7555442

[82] Kim EY,Kim JE,Kim SM.Interleukin-22 mediates the chemotactic migration of breast cancer cells and macrophage infiltration of the bone microenvironment by potentiating S1P/SIPR signaling.Cells2020;9:131 PMCID:PMC7017200

[83] Filipenko I,Reali L.Upregulation of the S1P(3) receptor in metastatic breast cancer cells increases migration and invasion by induction of PGE(2) and EP(2)/EP(4) activation.Biochimica et biophysica acta2016;1861:1840-51

[84] Stayrook KR,Cerabona D.TGFβ-mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis.Bonekey Rep2015;4:719 PMCID:PMC4495778

[85] Sowder ME.Bone as a preferential site for metastasis.JBMR Plus2019;3:e10126 PMCID:PMC6419612

[86] Bouquerel P,Müller D.Essential role for SphK1/S1P signaling to regulate hypoxia-inducible factor 2α expression and activity in cancer.Oncogenesis2016;5:e209 PMCID:PMC4815047

[87] Gstalder C,Cuvillier O.FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model.Mol Cancer Ther2016;15:2465-74

[88] Xu Y,Wang J,Xue W.Sphingosine kinase 1 overexpression contributes to sunitinib resistance in clear cell renal cell carcinoma.Oncoimmunology2018;7:e1502130 PMCID:PMC6279321

[89] Zhang L,Bullock AJ.Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.Clin Cancer Res2015;21:1925-34 PMCID:PMC4419371

[90] Pal SK,Reeves JA.A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma.Cancer2017;123:576-82

[91] Schneider G,Bujko K,Kucia M.Novel pleiotropic effects of bioactive phospholipids in human lung cancer metastasis.Oncotarget2017;8:58247-63 PMCID:PMC5601648

[92] Ader I,Bouquerel P.Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer.Oncotarget2015;6:13803-21 PMCID:PMC4537051

[93] Brizuela L,Mazerolles C,Malavaud B.First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer.Mol Cancer Ther2012;11:1841-51

[94] Malavaud B,Mazerolles C.Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens.Eur J Cancer2010;46:3417-24

[95] Brizuela L,Jeannot P.Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells.Mol Oncol2014;8:1181-95 PMCID:PMC5528572

[96] Bao Y,Zhang C,Yang W.Sphingosine Kinase 1 and Sphingosine-1-Phosphate Signaling in Colorectal Cancer.Int J Mol Sci2017;18:2109 PMCID:PMC5666791

[97] Grbčić P.Sphingosine 1-Phosphate Signaling and Metabolism in Chemoprevention and Chemoresistance in Colon Cancer.Molecules2020;25:2436 PMCID:PMC7287727

[98] Liu SQ,Wu WH.Sphingosine kinase 1 promotes the metastasis of colorectal cancer by inducing the epithelialmesenchymal transition mediated by the FAK/AKT/MMPs axis.Int J Oncol2019;54:41-52 PMCID:PMC6254930

[99] Bae GE,Kim K,Cho S.Increased Sphingosine Kinase 1 Expression Predicts Distant Metastasis and Poor Outcome in Patients With Colorectal Cancer.Anticancer Res2019;39:663-70

[100] Schwiebs A,Schmidt KG.Cancer-induced inflammation and inflammation-induced cancer in colon: a role for S1P lyase.Oncogene2019;38:4788-803

[101] Gu X,Xue W.SPNS2 promotes the malignancy of colorectal cancer cells via regulating Akt and ERK pathway.Clin Exp Pharmacol Physiol2019;46:861-71

[102] Zhang YH,Wan SB,Qu XJ.Increased S1P induces S1PR2 internalization to blunt the sensitivity of colorectal cancer to 5-fluorouracil via promoting intracellular uracil generation.Acta Pharmacol Sin2021;42:460-9 PMCID:PMC8027438

[103] Olesch C,Berkefeld M.S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion.J Clin Invest2020;130:5461-76 PMCID:PMC7524469

[104] Mitchell JA.Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy.Br J Pharmacol1999;128:1121-32 PMCID:PMC1571744

[105] Wang D.Eicosanoids and cancer.Nat Rev Cancer2010;10:181-93 PMCID:PMC2898136

[106] Peters-Golden M.Leukotrienes.N Engl J Med2007;357:1841-54

[107] Yokomizo T,Chang K,Shimizu T.A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis.Nature1997;387:620-4

[108] Bäck M,Dahlén SE.Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7.Br J Pharmacol2014;171:3551-74 PMCID:PMC4128057

[109] Lynch KR,Liu Q.Characterization of the human cysteinyl leukotriene CysLT1 receptor.Nature1999;399:789-93

[110] Heise CE,Figueroa DJ.Characterization of the human cysteinyl leukotriene 2 receptor.J Biol Chem2000;275:30531-6

[111] Pilbeam CC,Raisz LG. Chapter 54 - Prostaglandins and Bone Metabolism. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of Bone Biology (Second Edition). San Diego: Academic Press; 2002. p. 979-94.

[112] Hikiji H,Yokomizo T,Shimizu T.A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss.Proc Natl Acad Sci U S A2009;106:21294-9 PMCID:PMC2795503

[113] Miyaura C,Suzawa T.Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice.J Biol Chem2000;275:19819-23

[114] Sakuma Y,Suda M.Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide.J Bone Miner Res2000;15:218-27

[115] Wani MR,Kim NS,Chambers T.Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion.Endocrinology1999;140:1927-35

[116] Kobayashi Y,Yamashita T.Prostaglandin E2 receptors EP2 and EP4 are downregulated during differentiation of mouse osteoclasts from their precursors.J Biol Chem2005;280:24035-42

[117] Yoshida K,Kobayashi T.Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation.Proc Natl Acad Sci U S A2002;99:4580-5 PMCID:PMC123690

[118] Alander CB.Effects of selective prostaglandins E2 receptor agonists on cultured calvarial murine osteoblastic cells.Prostaglandins Other Lipid Mediat2006;81:178-83 PMCID:PMC1864935

[119] Forwood MR.Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo.J Bone Miner Res1996;11:1688-93

[120] Bonewald LF,Qiao M,Mundy GR.Mice lacking 5-lipoxygenase have increased cortical bone thickness.Adv Exp Med Biol1997;433:299-302

[121] Le P,Bornstein S,Horowitz MC.A high-fat diet induces bone loss in mice lacking the Alox5 gene.Endocrinology2012;153:6-16 PMCID:PMC3249675

[122] Moura AP,Queiroz-Junior CM.The relevance of leukotrienes for bone resorption induced by mechanical loading.Bone2014;69:133-8

[123] Madeira MFM,Corrêa JD.The role of 5-lipoxygenase in Aggregatibacter actinomycetemcomitans-induced alveolar bone loss.J Clin Periodontol2017;44:793-802

[124] Zheng LX,Hong FF.Pain and bone damage in rheumatoid arthritis: role of leukotriene B4. Clinical and experimental rheumatology. 2019;37:872-8.

[125] Lee JM,Noh AL.5-Lipoxygenase mediates RANKL-induced osteoclast formation via the cysteinyl leukotriene receptor 1.J Immunol2012;189:5284-92

[126] Kang JH,Lee DS.Montelukast inhibits RANKLinduced osteoclast formation and bone loss via CysLTR1 and P2Y12.Mol Med Rep2018;18:2387-98

[127] Zheng C.Cysteinyl leukotriene receptor 1 (cysLT1R) regulates osteoclast differentiation and bone resorption.Artif Cells Nanomed Biotechnol2018;46:S64-70

[128] Lee NK,Baik JY.A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation.Blood2005;106:852-9

[129] Luo X,Loza AJ.Stromal-initiated changes in the bone promote metastatic niche development.Cell Rep2016;14:82-92 PMCID:PMC4706805

[130] Wei J,Huang C.The cysteinyl leukotriene receptor 1 (CysLT1R) antagonist montelukast suppresses matrix metalloproteinase-13 expression induced by lipopolysaccharide.Int Immunopharmacol2018;55:193-7

[131] Boehmler AM,Jaggy L.The CysLT1 ligand leukotriene D4 supports alpha4beta1- and alpha5beta1-mediated adhesion and proliferation of CD34+ hematopoietic progenitor cells.J Immunol2009;182:6789-98

[132] Drost AC,Boehmler A.The G protein-coupled receptor CysLT1 mediates chemokine-like effects and prolongs survival in chronic lymphocytic leukemia.Leuk Lymphoma2012;53:665-73

[133] Finetti F,Ercoli J,Buoso E.Prostaglandin E2 and cancer: insight into tumor progression and immunity.Biology (Basel)2020;9:434 PMCID:PMC7760298

[134] Montezuma MAP,Benites BM.COX-2 as a determinant of lower disease-free survival for patients affected by ameloblastoma.Pathol Res Pract2018;214:907-13

[135] Sun H,Sun D.COX-2 expression in ovarian cancer: an updated meta-analysis.Oncotarget2017;8:88152-62 PMCID:PMC5675700

[136] Esbona K,Saha S.The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients.Am J Pathol2018;188:559-73 PMCID:PMC5963475

[137] Rothwell PM,Price JF,Meade TW.Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.Lancet2012;379:1591-601

[138] Charalambous MP,Bhambra U,Gooderham NJ.Colorectal Cancer Study GroupUpregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells.Br J Cancer2003;88:1598-604 PMCID:PMC2377108

[139] Harris RE.Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung.Inflammopharmacology2009;17:55-67

[140] Cui Y,Li HL.Prospective study of urinary prostaglandin E2 metabolite and pancreatic cancer risk.Int J Cancer2017;141:2423-9 PMCID:PMC5749224

[141] Miao J,Hu Y.Prostaglandin E(2) and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment.Oncotarget2017;8:89802-10 PMCID:PMC5685710

[142] Hansen-Petrik MB,Jull B,Zemel MB.Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.Cancer Res2002;62:403-8

[143] Myung SJ,Yan M.15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.Proc Natl Acad Sci U S A2006;103:12098-102 PMCID:PMC1567703

[144] Yan M,Fink SP.15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.Proc Natl Acad Sci U S A2009;106:9409-13 PMCID:PMC2695050

[145] Nakanishi M,Tanaka T.Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity.Cancer Prev Res (Phila)2011;4:1198-208 PMCID:PMC3151318

[146] Howe LR,Kent CV.Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis.Prostaglandins Other Lipid Mediat2013;106:99-105 PMCID:PMC3830707

[147] O'Callaghan G.Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?.Br J Pharmacol2015;172:5239-50 PMCID:PMC5341220

[148] Uluçkan O,Floyd DH.APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice.J Cell Biochem2008;104:1311-23 PMCID:PMC2763643

[149] Inada M,Yokoyama S.Direct Melanoma Cell Contact Induces Stromal Cell Autocrine Prostaglandin E2-EP4 Receptor Signaling That Drives Tumor Growth, Angiogenesis, and Metastasis.J Biol Chem2015;290:29781-93 PMCID:PMC4706013

[150] Hiraga T,Choi ME,Yoneda T.Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.Cancer Res2006;66:2067-73

[151] Singh B,Shoher A.COX-2 induces IL-11 production in human breast cancer cells.J Surg Res2006;131:267-75

[152] Singh B,Vincent LE.Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer.J Surg Res2006;134:44-51

[153] Xu S,Ge J.Prostaglandin E2 receptor EP4 is involved in the cell growth and invasion of prostate cancer via the cAMPPKA/PI3KAkt signaling pathway.Mol Med Rep2018;17:4702-12

[154] Karavitis J.COX2 regulation of breast cancer bone metastasis.Oncoimmunology2013;2:e23129 PMCID:PMC3661150

[155] Singh B,Shoher A,Wei C.COX-2 involvement in breast cancer metastasis to bone.Oncogene2007;26:3789-96

[156] Watanabe K,Hirata M.Abrogation of prostaglandin E-EP4 signaling in osteoblasts prevents the bone destruction induced by human prostate cancer metastases.Biochem Biophys Res Commun2016;478:154-61

[157] Gupta S,Ahmad N,Bostwick DG.Lipoxygenase-5 is overexpressed in prostate adenocarcinoma.Cancer2001;91:737-43

[158] Knab LM,Bentrem DJ.Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.World J Gastroenterol2014;20:10729-39 PMCID:PMC4138453

[159] Yoshimura R,Tsuchida K,Sano H.Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors.J Urol2003;170:1994-9

[160] Hoque A,Wu TT.Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention.Carcinogenesis2005;26:785-91

[161] Matsuyama M,Mitsuhashi M.5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.Oncol Rep2005;14:73-9

[162] Steinhilber D,Metzner J.5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis.Front Pharmacol2010;1:143 PMCID:PMC3153017

[163] Magnusson C,Olsen J.An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation.Cancer Res2007;67:9190-8

[164] Tornhamre S,Granzelius A.Inverse relationship between myeloid maturation and leukotriene C4 synthase expression in normal and leukemic myelopoiesis-consistent overexpression of the enzyme in myeloid cells from patients with chronic myeloid leukemia.Exp Hematol2003;31:122-30

[165] Ali HEA,Sholl AB.Dysregulated gene expression predicts tumor aggressiveness in African-American prostate cancer patients.Sci Rep2018;8:16335 PMCID:PMC6218553

[166] Paruchuri S,Juhas M,Sjölander A.Leukotriene D(4) activates MAPK through a Ras-independent but PKCepsilon-dependent pathway in intestinal epithelial cells.J Cell Sci2002;115:1883-93

[167] Mezhybovska M,Ohd JF.The inflammatory mediator leukotriene D4 induces beta-catenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells.J Biol Chem2006;281:6776-84

[168] Massoumi R,Azemovic D.Leukotriene D4-induced adhesion of Caco-2 cells is mediated by prostaglandin E2 and upregulation of α2β1-integrin.Exp Cell Res2003;289:342-51

[169] Salim T,Sjölander A.The inflammatory mediator leukotriene D4 induces subcellular β-catenin translocation and migration of colon cancer cells.Exp Cell Res2014;321:255-66

[170] Chen X,Wang S.Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin.J Natl Cancer Inst2003;95:1053-61

[171] Zhao S,Li D.Inhibition of LTA4H by bestatin in human and mouse colorectal cancer.EBioMedicine2019;44:361-74 PMCID:PMC6604047

[172] Tong WG,Talamonti MS,Adrian TE.LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways.Biochem Biophys Res Commun2005;335:949-56

[173] Ihara A,Yoneda M,Takahashi H.Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer.J Pharmacol Sci2007;103:24-32

[174] Kim H,Kim JH.Ras promotes transforming growth factor-β (TGF-β)-induced epithelial-mesenchymal transition via a leukotriene B4 receptor-2-linked cascade in mammary epithelial cells.J Biol Chem2014;289:22151-60 PMCID:PMC4139228

[175] Tian W,Sung YK.Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.Circulation2019;140:1409-25 PMCID:PMC6803052

[176] Chheda ZS,Jala VR,Haribabu B.Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors.J Immunol2016;197:2016-26 PMCID:PMC4992661

[177] Edelman MJ,Wang X.Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.J Clin Oncol2008;26:848-55

[178] Jänne PA,Oh Y.Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer.J Thorac Oncol2014;9:126-31

[179] Tsai MJ,Sheu CC.Cysteinyl leukotriene receptor antagonists decrease cancer risk in asthma patients.Sci Rep2016;6:23979 PMCID:PMC4823742

[180] Gunning WT,Steele VE.Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice.Cancer Res2002;62:4199-201

[181] Nozaki M,Ishitani K.Cysteinyl leukotriene receptor antagonists inhibit tumor metastasis by inhibiting capillary permeability.Keio J Med2010;59:10-8 PMCID:PMC3397318

[182] Jose MA,Sathyamurthy D.Chemopreventive effect of montelukast in n-nitroso n-methyl urea induced mammary carcinogenesis in female Sprague-Dawley rats.Indian J Pharmacol2013;45:286-8 PMCID:PMC3696303

[183] Savari S,Zhang Y,Sjölander A.CysLT(1)R antagonists inhibit tumor growth in a xenograft model of colon cancer.PLoS One2013;8:e73466 PMCID:PMC3764114

[184] Satapathy SR.Cysteinyl leukotriene receptor 1 promotes 5-fluorouracil resistance and resistance-derived stemness in colon cancer cells.Cancer Lett2020;488:50-62

[185] Tumber A,Meikle MC.Human breast-cancer cells stimulate the fusion, migration and resorptive activity of osteoclasts in bone explants.Int J Cancer2001;91:650-3

[186] Poczobutt JM,Hanson D.Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment.J Immunol2016;196:891-901 PMCID:PMC4705594

[187] Balkwill F.Inflammation and cancer: back to Virchow?.Lancet2001;357:539-45

[188] Fishbein A,Yang H.Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression.Proc Natl Acad Sci U S A2020;117:21576-87 PMCID:PMC7474612

[189] Camphausen K,Beecken WD,Folkman J.Radiation therapy to a primary tumor accelerates metastatic growth in mice.Cancer Res2001;61:2207-11

[190] Chang J,Bielenberg DR.Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin.FASEB J2019;33:114-25 PMCID:PMC6355061

[191] Filippou PS.Cytokine storm during chemotherapy: a new companion diagnostic emerges?.Oncotarget2020;11:213-5 PMCID:PMC6980630

[192] Gartung A,Sukhatme VP.Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor.Proc Natl Acad Sci U S A2019;116:1698-703 PMCID:PMC6358686

[193] Karagiannis GS,Wang Y.Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism.Sci Transl Med2017;9:eaan0026 PMCID:PMC5592784

[194] Shaked Y.The pro-tumorigenic host response to cancer therapies.Nat Rev Cancer2019;19:667-85

[195] Volk-Draper L,Griggs C.Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner.Cancer Res2014;74:5421-34 PMCID:PMC4185415

[196] Sulciner ML,Gilligan MM.Resolvins suppress tumor growth and enhance cancer therapy.J Exp Med2018;215:115-40 PMCID:PMC5748851

[197] Gilligan MM,Sulciner ML.Aspirin-triggered proresolving mediators stimulate resolution in cancer.Proc Natl Acad Sci U S A2019;116:6292-7 PMCID:PMC6442621

[198] Liu H,Huang W.Colorectal cancer is associated with a deficiency of Lipoxin A(4), an endogenous anti-inflammatory mediator.J Cancer2019;10:4719-30 PMCID:PMC6746129

[199] Panigrahy D,Lee CR.Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice.J Clin Invest2012;122:178-91 PMCID:PMC3248288

[200] Serhan CN.Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.J Clin Invest2018;128:2657-69 PMCID:PMC6025982

[201] Sulciner ML,Gilligan MM,Panigrahy D.Targeting lipid mediators in cancer biology.Cancer Metastasis Rev2018;37:557-72

[202] Ye Y,Bernabé D.Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma.Neuropharmacology2018;139:182-93

[203] Serhan CN.The resolution of inflammation: the devil in the flask and in the details.FASEB J2011;25:1441-8 PMCID:PMC3228345

[204] Sharma P.The future of immune checkpoint therapy.Science2015;348:56-61

[205] Serhan CN.Pro-resolving lipid mediators are leads for resolution physiology.Nature2014;510:92-101 PMCID:PMC4263681

[206] Fishbein A,Serhan CN.Carcinogenesis: Failure of resolution of inflammation?.Pharmacol Ther2021;218:107670 PMCID:PMC7470770

[207] Chiang N,Dahlén SE.The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo.Pharmacol Rev2006;58:463-87

[208] Liu C,Cai C,Xiao J.Lipoxin A4 suppresses osteoclastogenesis in RAW264.7 cells and prevents ovariectomy-induced bone loss.Exp Cell Res2017;352:293-303